ICER updates cost-effectiveness estimates for CGRP inhibitors for migraines

ICER released an evidence report May 31 evaluating calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention that calculated more favorable long-term cost-effectiveness ratios than in its April draft evidence report. ICER updated the cost-effectiveness analyses using the list price for recently approved Aimovig erenumab from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN).

ICER's draft evidence report published April 11 used a placeholder annual wholesale acquisition cost (WAC) of $8,500 in its calculations for Aimovig and fremanezumab, as both therapies were under FDA review at the time. FDA subsequently approved Aimovig to prevent migraine in adults and Amgen launched the drug with an annual WAC of $6,900. Fremanezumab (TEV-48125) from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) is still under FDA review. In May, Teva said it does not expect FDA to approve the BLA by its mid-June PDUFA date...